Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Published

Journal Article

The generation of antiviral cytotoxic T lymphocytes (CTLs) is a critical component of the immune response to viral infections. A safe and nontoxic vaccine for AIDS would optimally use a carrier-free synthetic peptide immunogen containing only components of HIV necessary for induction of protective immune responses. We report that hybrid synthetic peptides containing either a HIV envelope gp120 T-cell determinant (T1) or the envelope gp41 fusion domain (F) N-terminal to HIV CTL determinants are capable of priming murine CD8+, major histocompatibility complex class I-restricted anti-HIV CTLs in vivo. These data demonstrate that carrier-free, nonderivatized synthetic peptides can be used in vivo to induce anti-HIV CTL responses.

Full Text

Duke Authors

Cited Authors

  • Hart, MK; Weinhold, KJ; Scearce, RM; Washburn, EM; Clark, CA; Palker, TJ; Haynes, BF

Published Date

  • November 1, 1991

Published In

Volume / Issue

  • 88 / 21

Start / End Page

  • 9448 - 9452

PubMed ID

  • 1946358

Pubmed Central ID

  • 1946358

International Standard Serial Number (ISSN)

  • 0027-8424

Digital Object Identifier (DOI)

  • 10.1073/pnas.88.21.9448

Language

  • eng

Conference Location

  • United States